Clinical Trial Update: Bisoprolol Administration to Prevent Anthracycline-induced Cardiotoxicity [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating bisoprolol to prevent anthracycline-induced cardiotoxicity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiomyopathy
• Chemotherapy-induced Cardiotoxicity
• Diastolic Dysfunction
• Systolic Dysfunction

Drugs mentioned

• Bisoprolol (Bisoprolol)

Snippet

Sponsor: Shahid Beheshti University of Medical Sciences | Conditions: Cardiomyopathies, Chemotherapy Effect | Phase 3 | Status: COMPLETED